Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. 2010

Ann J Hessell, and Eva G Rakasz, and David M Tehrani, and Michael Huber, and Kimberly L Weisgrau, and Gary Landucci, and Donald N Forthal, and Wayne C Koff, and Pascal Poignard, and David I Watkins, and Dennis R Burton
Department of Immunology and Microbial Science and the International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92037, USA.

The membrane-proximal external region (MPER) of HIV-1, located at the C terminus of the gp41 ectodomain, is conserved and crucial for viral fusion. Three broadly neutralizing monoclonal antibodies (bnMAbs), 2F5, 4E10, and Z13e1, are directed against linear epitopes mapped to the MPER, making this conserved region an important potential vaccine target. However, no MPER antibodies have been definitively shown to provide protection against HIV challenge. Here, we show that both MAbs 2F5 and 4E10 can provide complete protection against mucosal simian-human immunodeficiency virus (SHIV) challenge in macaques. MAb 2F5 or 4E10 was administered intravenously at 50 mg/kg to groups of six male Indian rhesus macaques 1 day prior to and again 1 day following intrarectal challenge with SHIV(Ba-L). In both groups, five out of six animals showed complete protection and sterilizing immunity, while for one animal in each group a low level of viral replication following challenge could not be ruled out. The study confirms the protective potential of 2F5 and 4E10 and supports emphasis on HIV immunogen design based on the MPER region of gp41.

UI MeSH Term Description Entries
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D015302 Simian Immunodeficiency Virus Species of the genus LENTIVIRUS, subgenus primate immunodeficiency viruses (IMMUNODEFICIENCY VIRUSES, PRIMATE), that induces acquired immunodeficiency syndrome in monkeys and apes (SAIDS). The genetic organization of SIV is virtually identical to HIV. SIV (Simian immunodeficiency virus),Immunodeficiency Viruses, Simian,Simian Immunodeficiency Viruses,Immunodeficiency Virus, Simian
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015700 HIV Envelope Protein gp41 Transmembrane envelope protein of the HUMAN IMMUNODEFICIENCY VIRUS which is encoded by the HIV env gene. It has a molecular weight of 41,000 and is glycosylated. The N-terminal part of gp41 is thought to be involved in CELL FUSION with the CD4 ANTIGENS of T4 LYMPHOCYTES, leading to syncytial formation. Gp41 is one of the most common HIV antigens detected by IMMUNOBLOTTING. Envelope Protein gp41, HIV,HIV Transmembrane Protein gp41,HTLV-III gp41,env Protein gp41, HIV,gp41(HIV),gp41 Envelope Protein, HIV
D057134 Antibodies, Neutralizing Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus. Neutralizing Antibodies,Antibody, Neutralizing,Neutralizing Antibody
D018928 Immunity, Mucosal Nonsusceptibility to the pathogenic effects of foreign microorganisms or antigenic substances as a result of antibody secretions of the mucous membranes. Mucosal epithelia in the gastrointestinal, respiratory, and reproductive tracts produce a form of IgA (IMMUNOGLOBULIN A, SECRETORY) that serves to protect these ports of entry into the body. Immune Response, Mucosal,Mucosal Immunity,Immune Responses, Mucosal,Mucosal Immune Response,Mucosal Immune Responses
D019562 Viral Load The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression. Viral Burden,Virus Titer,Burden, Viral,Load, Viral,Titer, Virus

Related Publications

Ann J Hessell, and Eva G Rakasz, and David M Tehrani, and Michael Huber, and Kimberly L Weisgrau, and Gary Landucci, and Donald N Forthal, and Wayne C Koff, and Pascal Poignard, and David I Watkins, and Dennis R Burton
November 2001, Journal of virology,
Ann J Hessell, and Eva G Rakasz, and David M Tehrani, and Michael Huber, and Kimberly L Weisgrau, and Gary Landucci, and Donald N Forthal, and Wayne C Koff, and Pascal Poignard, and David I Watkins, and Dennis R Burton
October 2009, Journal of virology,
Ann J Hessell, and Eva G Rakasz, and David M Tehrani, and Michael Huber, and Kimberly L Weisgrau, and Gary Landucci, and Donald N Forthal, and Wayne C Koff, and Pascal Poignard, and David I Watkins, and Dennis R Burton
April 2007, Journal of virology,
Ann J Hessell, and Eva G Rakasz, and David M Tehrani, and Michael Huber, and Kimberly L Weisgrau, and Gary Landucci, and Donald N Forthal, and Wayne C Koff, and Pascal Poignard, and David I Watkins, and Dennis R Burton
December 2015, Virologica Sinica,
Ann J Hessell, and Eva G Rakasz, and David M Tehrani, and Michael Huber, and Kimberly L Weisgrau, and Gary Landucci, and Donald N Forthal, and Wayne C Koff, and Pascal Poignard, and David I Watkins, and Dennis R Burton
January 2005, Journal of virology,
Ann J Hessell, and Eva G Rakasz, and David M Tehrani, and Michael Huber, and Kimberly L Weisgrau, and Gary Landucci, and Donald N Forthal, and Wayne C Koff, and Pascal Poignard, and David I Watkins, and Dennis R Burton
December 1994, AIDS research and human retroviruses,
Ann J Hessell, and Eva G Rakasz, and David M Tehrani, and Michael Huber, and Kimberly L Weisgrau, and Gary Landucci, and Donald N Forthal, and Wayne C Koff, and Pascal Poignard, and David I Watkins, and Dennis R Burton
November 2009, Journal of virology,
Ann J Hessell, and Eva G Rakasz, and David M Tehrani, and Michael Huber, and Kimberly L Weisgrau, and Gary Landucci, and Donald N Forthal, and Wayne C Koff, and Pascal Poignard, and David I Watkins, and Dennis R Burton
September 2008, Journal of virology,
Ann J Hessell, and Eva G Rakasz, and David M Tehrani, and Michael Huber, and Kimberly L Weisgrau, and Gary Landucci, and Donald N Forthal, and Wayne C Koff, and Pascal Poignard, and David I Watkins, and Dennis R Burton
February 2000, Nature medicine,
Ann J Hessell, and Eva G Rakasz, and David M Tehrani, and Michael Huber, and Kimberly L Weisgrau, and Gary Landucci, and Donald N Forthal, and Wayne C Koff, and Pascal Poignard, and David I Watkins, and Dennis R Burton
October 2006, AIDS research and human retroviruses,
Copied contents to your clipboard!